Brokerages Set LifeMD, Inc. (NASDAQ:LFMD) Price Target at $11.57

LifeMD, Inc. (NASDAQ:LFMD) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $11.57.

LFMD has been the topic of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of LifeMD in a research report on Monday, November 11th. Lake Street Capital started coverage on shares of LifeMD in a research report on Tuesday, December 10th. They set a “buy” rating and a $12.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $15.00 price target on shares of LifeMD in a report on Friday, September 20th. Finally, Mizuho began coverage on shares of LifeMD in a report on Wednesday, December 4th. They set a “neutral” rating and a $7.00 price objective on the stock.

LifeMD Stock Down 1.6 %

LFMD stock opened at $4.91 on Friday. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.83 and a quick ratio of 0.78. The company has a 50-day moving average of $5.39 and a two-hundred day moving average of $5.75. The stock has a market capitalization of $212.66 million, a price-to-earnings ratio of -7.67 and a beta of 1.38. LifeMD has a 52-week low of $3.99 and a 52-week high of $12.88.

Insider Activity at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.52, for a total transaction of $163,000.00. Following the completion of the transaction, the chief executive officer now directly owns 2,728,715 shares in the company, valued at $17,791,221.80. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 15.97% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LifeMD

Several large investors have recently made changes to their positions in the company. State Street Corp boosted its position in LifeMD by 20.0% in the third quarter. State Street Corp now owns 1,155,495 shares of the company’s stock valued at $6,055,000 after buying an additional 192,861 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of LifeMD by 14.6% in the 3rd quarter. Royce & Associates LP now owns 901,041 shares of the company’s stock worth $4,721,000 after acquiring an additional 114,710 shares in the last quarter. Los Angeles Capital Management LLC grew its position in LifeMD by 852.6% during the 3rd quarter. Los Angeles Capital Management LLC now owns 121,585 shares of the company’s stock worth $637,000 after acquiring an additional 108,822 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in LifeMD by 63.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 234,583 shares of the company’s stock valued at $1,609,000 after purchasing an additional 91,183 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in LifeMD by 11.4% in the 3rd quarter. Geode Capital Management LLC now owns 819,233 shares of the company’s stock valued at $4,293,000 after purchasing an additional 83,598 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.